Patents by Inventor Scott J. Rodig

Scott J. Rodig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 11723972
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: August 15, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Fundacion Sales
    Inventors: Margaret Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
    Patent number: 11673956
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: June 13, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20210095035
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 1, 2021
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
    Patent number: 10948492
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness of esophagogastric cancers to inhibitors of the PD-1 pathway.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adam Bass, Sarah Derks, Gordon J. Freeman, Scott J. Rodig
  • Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1
    Patent number: 10844126
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1
    Publication number: 20200093920
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 26, 2020
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego O. Russo, Mariana Salatino
  • Anti-galectin-1 monoclonal antibodies and fragments thereof
    Patent number: 10519238
    Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: December 31, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 10456465
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 29, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, AND MONITORING OF IMMUNE DISORDERS USING GALECTIN-1
    Publication number: 20190212330
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 11, 2019
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20190127473
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: July 31, 2018
    Publication date: May 2, 2019
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • PD-L2 BIOMARKERS PREDICTIVE OF PD-1 PATHWAY INHIBITOR RESPONSES IN ESOPHAGOGASTRIC CANCERS
    Publication number: 20180238884
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness of esophagogastric cancers to inhibitors of the PD-1 pathway.
    Type: Application
    Filed: March 3, 2016
    Publication date: August 23, 2018
    Inventors: Adam Bass, Sarah Derks, Gordon J. Freeman, Scott J. Rodig
  • Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
    Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • CLASSIFICATION OF MYC-DRIVEN B-CELL LYMPHOMAS
    Publication number: 20170029904
    Abstract: Methods for diagnosing Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) based on a diagnostic score, as well as determining MYC activity levels and selecting treatments based on a MYC activity score.
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Inventors: Scott J. Rodig, Christopher Daniel Carey, Margaret A. Shipp, Stefano Monti, Daniel Gusenleitner, Bjoern Chapuy
  • ANTI-GALECTIN-1 (GAL1) MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF FOR NEUTRALIZING GAL1
    Publication number: 20160215052
    Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
    Type: Application
    Filed: July 23, 2014
    Publication date: July 28, 2016
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1
    Publication number: 20160187340
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 30, 2016
    Inventors: Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich
  • ANTI-GALECTIN-1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20160168236
    Abstract: The present invention is based, in part, on the discovery of anti-galectm-1 (Gal 1.) monodonai antibodies useful for diagnostic and prognostic applications, as well as immunoglobulins, polypeptides, and nucleic acids thereof.
    Type: Application
    Filed: July 23, 2014
    Publication date: June 16, 2016
    Inventors: Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
    Publication number: 20150191536
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 9, 2015
    Applicants: The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
    Patent number: 8968740
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 3, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Compositions, Kits, and Methods for the Identification, Assessment, Prevention, and Therapy of Cancer
    Publication number: 20150004158
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
    Publication number: 20130011409
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 10, 2013
    Applicants: Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Dana-Farber-Cancer Institute, Inc.
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino